2nd Line Relapsed or Metastatic Mucosal HNSCC not NPC

Treatment

No Injectable Lesions

Max 2 Prior Therapies

Prior C Injectable Lesions

ECOG-ACRIN-EA3202
Phase II/III Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent / Metastatic Head & Neck Cancers
PI: Khan Sponsor: ECOG-ACRIN

ENT0100
Phase I Multicenter Open Label First-in-Human ABBV-CL5-579 Alone and in Combination in Locally Advanced or Metastatic Tumors PI: Colevas Sponsor: AbbVie Inc.

ENT0088
Phase II Macrolimab Combination Therapy in Head and Neck Squamous Cell Carcinoma Safety Run-in 2 / Phase 2 Cohort 3 PI: Colevas Sponsor: Gilead Sciences, Inc.

ENT0064
Phase Ib Ad/PNP-P-araAAMP + Co-Admin of Fludarabine Phosphate in Recurrent Local Head and Neck Cancer PI: Colevas Sponsor: PNP Therapeutics

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu